Merit Medical Systems (MMSI) Stock May Be 29% Undervalued On Product Expansion News
Merit Medical Systems stock has delivered a modest 15.2% gain over the past five years, and today its valuation signals are split. The Discounted Cash Flow (DCF) intrinsic value estimate points to meaningful upside, while earnings-based multiples suggest the shares trade at a premium. That tension leaves investors weighing a DCF view that screens the stock as undervalued against a market multiple read that looks less forgiving.
- Over five years, Merit Medical Systems has returned 15.2%, which is a steady outcome rather than a dramatic win or loss for long term holders.
- Recent coverage highlighting product launches and acquisitions in oncology and endoscopy can support growth expectations, while tariffs, trade policy and pressure in China and the OEM business may limit how much investors are willing to pay for that growth.
- On Simply Wall St's broader valuation checks, Merit Medical Systems scores 4 out of 6, which points to a mixed picture rather than a clear bargain or clear overvaluation.
The issue now is whether Merit Medical Systems' current share price already reflects these growth and risk factors, or if the intrinsic value estimate that suggests the stock is 29.3% below fair value is closer to the mark.
Is Merit Medical Systems a Bargain on Cash Flow?
The Discounted Cash Flow (DCF) model uses Merit Medical Systems' projected future cash flows to estimate what the stock could be worth today. In this framework, the company’s latest twelve month free cash flow of about $237.7 million is treated as growing steadily rather than surging or shrinking, and then discounted back using a two-stage approach.
That stream of projected cash flows leads to an estimated intrinsic value of about $104.62 per share, which is roughly 29.3% above the current share price estimate used in this model, so the stock screens as undervalued on this basis. Recent commentary highlighting new products and acquisitions in oncology and endoscopy provides context for why cash flow projections support a higher value, even though factors such as tariffs and China exposure may be contributing to a more cautious stance in the market.
On the DCF numbers alone, Merit Medical Systems stock currently appears undervalued relative to the cash flows implied in this model.
Our Discounted Cash Flow (DCF) analysis suggests Merit Medical Systems is undervalued by 29.3%. Track this in your watchlist or portfolio, or discover 47 more high quality undervalued stocks.
Does Merit Medical Systems Look Pricey on Earnings?
The P/E multiple is a natural fit for Merit Medical Systems because earnings are a key driver of how investors usually value established medical equipment companies. Merit Medical Systems currently trades at about 31.7x earnings, which sits above the Medical Equipment industry average of roughly 27.5x and below the broader peer group around 43.4x. That puts the stock on a richer earnings multiple than the sector overall, but not at the very top end of its peer set.
Simply Wall St’s model suggests a fair P/E of about 23.1x for Merit Medical Systems given its profile, which is materially lower than the current 31.7x. This gap indicates the stock screens as overvalued on earnings, even though some investors may see product launches and acquisitions as reasons to accept a higher multiple. Put simply, the market is asking investors to pay a premium to the earnings level implied by this fair-value framework.
On the P/E yardstick, Merit Medical Systems stock currently looks overvalued relative to the earnings multiple the model treats as reasonable.
See what the numbers say about this price — find out in our valuation breakdown.
The Merit Medical Systems Narrative: What Would Justify Today's Price?
Simply Wall St Narratives for Merit Medical Systems are designed to bridge the gap between the DCF upside case and the richer P/E multiple you have just seen. They do this by spelling out which assumptions about Merit Medical Systems' future growth, margins and earnings would need to hold for the stock to be worth materially more or less than today's price. Instead of giving you just a single number from a model or ratio, they describe the future that number relies on so you can watch how reality lines up with it over time on the Community page.
One of the top community narratives on Merit Medical Systems: 33% undervalued
"Merit’s focus on higher margin platforms such as oncology, endoscopy, cardiac therapies and vascular intervention, supported by tuck in acquisitions like Biolife, C2 CryoBalloon and View Point that have strong gross margin profiles, is designed to shift the mix toward therapeutic products and support non GAAP gross margin and operating margin improvement over time…"
Read one of the top narratives on Merit Medical Systems
Do you think there's more to the story for Merit Medical Systems? Head over to our Community to see what others are saying!
The Bottom Line
For Merit Medical Systems, the Discounted Cash Flow (DCF) intrinsic value estimate points to meaningful upside, while the P/E view flags the stock as overvalued on earnings. That split largely reflects a cash flow model that leans on the timing and durability of free cash generation versus a market multiple that embeds higher expectations and current sentiment for growth peers. With broader valuation checks sitting in a mixed zone, the key question from here is whether margins and earnings progress in oncology and endoscopy are strong enough to keep justifying a premium multiple rather than the current discount being a value trap.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com